Regulatory · source year

2016 regulatory records

21 selected, source-linked regulatory records dated 2016. This is selective source coverage, not a complete timeline.

Dated records

21 selected records.

Peptide profiles

14 connected profiles.

Cited sources

21 distinct public records.

Cited chronology

Dated source records

All record types in 2016 →

December 2016

2 records

Dulaglutide

Federal Register notice 2016-30399

The Federal Register published notice 2016-30399, attributed to FDA and its parent HHS department, on 2016-12-19. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; TRULICITY,” and PeptideScanner's exact reviewed identity mapping connects the document to Dulaglutide.

Source: Federal Register via GovInfo ↗

→

November 2016

4 records

Melanotan II

Federal Register notice 2016-27244

The Federal Register published notice 2016-27244, attributed to FDA and its parent HHS department, on 2016-11-14. Its official title is “Edward Manookian (Also Known as Ed Manning): Debarment Order,” and PeptideScanner's exact reviewed identity mapping connects the document to Melanotan II.

Source: Federal Register via GovInfo ↗

→

October 2016

1 record

September 2016

2 records

Metreleptin

Federal Register notice 2016-22935

The Federal Register published notice 2016-22935, attributed to FDA and its parent HHS department, on 2016-09-23. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; MYALEPT,” and PeptideScanner's exact reviewed identity mapping connects the document to Metreleptin.

Source: Federal Register via GovInfo ↗

→

July 2016

1 record

June 2016

5 records

Desmopressin

Federal Register notice 2016-14418

The Federal Register published notice 2016-14418, attributed to FDA and its parent HHS department, on 2016-06-20. Its official title is “Bone, Reproductive and Urologic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.

Source: Federal Register via GovInfo ↗

→

Albiglutide

Federal Register notice 2016-13797

The Federal Register published notice 2016-13797, attributed to FDA and its parent HHS department, on 2016-06-10. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; TANZEUM,” and PeptideScanner's exact reviewed identity mapping connects the document to Albiglutide.

Source: Federal Register via GovInfo ↗

→

Oxytocin

Federal Register rule 2016-13517

The Federal Register published rule 2016-13517, attributed to FDA and its parent HHS department, on 2016-06-08. Its official title is “New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Applications; Changes of Sponsorship,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.

Source: Federal Register via GovInfo ↗

→

April 2016

3 records

Glatiramer acetate

Federal Register notice 2016-08682

The Federal Register published notice 2016-08682, attributed to FDA and its parent HHS department, on 2016-04-15. Its official title is “Product-Specific Bioequivalence Recommendations; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glatiramer.

Source: Federal Register via GovInfo ↗

→

March 2016

3 records

Liraglutide

Federal Register notice 2016-05959

The Federal Register published notice 2016-05959, attributed to FDA and its parent HHS department, on 2016-03-17. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide.

Source: Federal Register via GovInfo ↗

→

Lixisenatide

Federal Register notice 2016-05931

The Federal Register published notice 2016-05931, attributed to FDA and its parent HHS department, on 2016-03-16. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Lixisenatide.

Source: Federal Register via GovInfo ↗

→